FDA label
What is Ingrezza used for?
Ingrezza contains valbenazine. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “INGREZZA and INGREZZA SPRINKLE are indicated for the treatment of adults with:”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Ingrezza?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Ingrezza, capsule
Indications and Usage, quoted from the label by Neurocrine Biosciences, Inc. (NDA209241). Cross-references to other label sections are left out.
INGREZZA and INGREZZA SPRINKLE are indicated for the treatment of adults with:
- tardive dyskinesia.
- chorea associated with Huntington’s disease.
Source: DailyMed label, set id 4c970164-cafb-421f-9eb5-c226ef0a3417, version 34, effective April 17, 2026. NDC 70370-1060, one of 3 listings for this product.
Questions
What is Ingrezza used for?
The FDA label says: “INGREZZA and INGREZZA SPRINKLE are indicated for the treatment of adults with:”
What drug class is Ingrezza?
FDA lists valbenazine in the Vesicular Monoamine Transporter 2 Inhibitor established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.
More on Ingrezza
- Is Ingrezza a controlled substance?Federal schedule
- Generic for IngrezzaFDA Orange Book
- Generic for INGREZZA SprinkleFDA Orange Book
- Vesicular Monoamine Transporter 2 Inhibitors listFDA drug class
- Ingrezza Medicare Part D coverageBy plan and state
- NDC 70370-1060Ingrezza NDC record
- NDC 70370-1080Ingrezza NDC record
- NDC 70370-2040Ingrezza NDC record